Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2017

Open Access 01-02-2017 | comment

My personal highlights of ESMO 2016

Authors: Dr. M. Dediu, Dr. A. Gerger, Dr. N. Zojer, Prof. R. Bartsch

Published in: memo - Magazine of European Medical Oncology | Issue 1/2017

Login to get access

Summary

Results of several clinically relevant studies were presented at the 2016 Annual Meeting of the European Society of Medical Oncology (ESMO). This article summerizes the personal highlights of three medical oncologists in their respective areas of expertise.
Literature
1.
Eggermont A, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial. LBA2.
2.
Reck M, Rodríguez-Abreu D, Robinson A, et al. KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50 %. LBA8.
3.
Hortobagyi G, Stemmer S, Burris H, et al. First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2−), advanced breast cancer (ABC). LBA1.
4.
Mirza MR, Monk B, Oza A, et al. A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). LBA3.
5.
Barlesi F, Park2K, Ciardiello F, et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. LBA44.
6.
Balar A, Bellmunt J, O’Donnell P, et al. Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study. LBA32.
7.
Galsky M, Retz M, Siefker-Radtke A, et al. Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study. LBA31.
8.
Ravaud A, Motzer R, Pandha H, et al. Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC). LBA11.
9.
Choueiri T, Halabi S, Sanford B, et al. CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. LBA30.
10.
Ellis M, Bondarenko I, Trishkina E, et al. FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer. LBA14.
11.
Special Session: Right or left metastatic colon cancer: Will the side change your treatment? Chairs: Ciardiello F, Tabernero J. October 10th, 2016.
Metadata
Title
My personal highlights of ESMO 2016
Authors
Dr. M. Dediu
Dr. A. Gerger
Dr. N. Zojer
Prof. R. Bartsch
Publication date
01-02-2017
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2017
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0314-8

Other articles of this Issue 1/2017

memo - Magazine of European Medical Oncology 1/2017 Go to the issue

short review

Breast cancer milestones 2007–2016

short review

Milestones in the systemic treatment of lung cancer

editorial

To print or not to print

editorial

memo: Official journal of the OeGHO and CECOG

short review

Milestones in gastric cancer

short review

Milestones in Chronic Lymphocytic Leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits